Picks of the week

The ethics of using CRISPR to improve the odds of savior siblings. This is when a couple tries to have another baby who is both healthy and a suitable donor “match” for their older kid (“Could editing the DNA of embryos with CRISPR help save people who are already alive?“, STAT News, Sept. 16).

Carl Zimmer explaining a CRISPR experiment carried out to understand why many cancer drugs fail (“Why Aren’t Cancer Drugs Better? The Targets Might Be Wrong”, New York Times, Sept. 11; see also the paper in Science Translational Medicine)

Comments Roundup. A sad week for CRISPR crops in EU

CRISPR sad day

A shortlist of articles capturing ag scientists’ dismay at the recent EU verdict affecting the future of CRISPR crops:

Science Media Centre, Expert reaction to Court of Justice of the European Union ruling that GMO rules should cover plant genome editing techniques

Matt Ridley, EU’s anti-GMO crusade is unscientific and harmful

Mark Lynas, Scientific community defeated by green groups in European court ruling on gene edited crops

Carl Zimmer, What is a genetically modified crop? A European ruling sows confusion

The Observer view on Europe’s ban on gene-editing crops

Wired, European ruling could slow Africa’s push for CRISPR crops

 

 

 

Ground-cherries: will they be the next berry crop?

physalis

Physalis fruits look like golden marbles, larger than a blueberry, smaller than a grape. Carl Zimmer tried one, liked the rich pineapple-orange taste and wrote about their crispy future in his new book (“She Has Her Mother’s Laugh: The Powers, Perversions, and Potential of Heredity”). Ground-cherries, as they are called, belong to the same family as tomatoes but are an impossible challenge for traditional breeding because they have four copies of each chromosome rather than two. Continue reading